SCHEMBL16626657

SCHEMBL16626657

CNCc1cn(S(=O)(=O)c2cccnc2)c2cc(Oc3ncc(F)cn3)ccc12

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 16/20 0.40
IDE P14735 1/20 0.36
DRD2 P14416 2/20 0.35
HTR1A P08908 1/20 0.33
HTR1D P28221 1/20 0.33
HTR1B P28222 1/20 0.33
HTR1E P28566 1/20 0.33
HTR1F P30939 1/20 0.33
HTR7 P34969 1/20 0.33
DRD3 P35462 1/20 0.33
RORC P51449 1/20 0.32
PDE4A P27815 1/20 0.32
PDE4B Q07343 1/20 0.32
PDE4C Q08493 1/20 0.32
PDE4D Q08499 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL16618863 0.99 HTR6 (0.39) HTR6IDEDRD2HTR1AHTR1D
SCHEMBL16626399 0.83 HTR6 (0.40) HTR6IDECYP3A4CYP2D6
SCHEMBL16626792 0.83 HTR6 (0.39) HTR6IDEDRD2HTR1AHTR1D
Hydrochloric Acid SCHEMBL16619176 0.82 HTR6 (0.39) HTR6IDEDRD2CYP3A4CYP2D6
SCHEMBL17971585 0.82 HTR6 (0.40) HTR6IDEPDE4APDE4BPDE4C
Hydrochloric Acid SCHEMBL16619054 0.82 HTR6 (0.38) HTR6IDEDRD2HTR1AHTR1D
SCHEMBL16626794 0.82 LMNA (0.47) HTR6CYP3A4
Hydrochloric Acid SCHEMBL16619290 0.81 LMNA (0.46) HTR6CYP3A4
SCHEMBL17971571 0.80 HTR6 (0.39) HTR6IDEDRD2HTR1AHTR1D
SCHEMBL17971584 0.80 PDE4A (0.41) HTR6IDEPDE4APDE4BPDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3052484-B1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAE WOONG PHARMA (KR) 2018-03-21 EP claimed
EP-3052484-B1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAE WOONG PHARMA (KR) 2018-03-21 EP disclosed
US-9676714-B2 Sulfonylindole derivatives and method for preparing the same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-13 US disclosed
US-9676714-B2 Sulfonylindole derivatives and method for preparing the same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-13 US disclosed
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2016-08-04 US disclosed
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2016-08-04 US disclosed
WO-2015050412-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME GIPR, PGC, SI HTR6 166/4885IDE 2586/4885DRD2 2007/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.